Fish oil in critical illness: Mechanisms and clinical applications

Critical Care Clinics

Volumn 26, Issue 3, 2010, Pages 501-514

  Stapleton, Renee D ^a   Martin, Julie M ^a   Mayer, Konstantin ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Acute lung injury; Critical illness; Fish oil; Mechanical ventilation; Omega 3 fatty acids; Sepsis

Indexed keywords

C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; EPOXYICOSATRIENOIC ACID; FISH OIL; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE B5; LINOLEIC ACID; LIPID; LIPOFUNDIN; LIPOVEN; OLIVE OIL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; OMEGAVEN; OXEPA; PROSTAGLANDIN E3; SOYBEAN OIL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE LUNG INJURY; ARTIFICIAL VENTILATION; CAUSE OF DEATH; CLINICAL TRIAL; CRITICAL ILLNESS; CYTOKINE PRODUCTION; ENTERAL FEEDING PUMP; HUMAN; HYPOXEMIA; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFLAMMATION; LUNG INFILTRATE; MEDIATOR RELEASE; NONHUMAN; OUTCOME ASSESSMENT; PARENTERAL NUTRITION; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SEPSIS; STRESS; UNITED STATES;

ACUTE LUNG INJURY; AUTOIMMUNE DISEASES; CRITICAL ILLNESS; FATTY ACIDS, OMEGA-3; FISH OILS; HUMANS; PARENTERAL NUTRITION; SEPSIS;

EID: 77954929084     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2010.04.009     Document Type: Review

References (80)

1. Simopoulos A.P. Essential fatty acids in health and chronic disease. Am J Clin Nutr 1999, 70(Suppl 3). 560S-9S.
2. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29(7):1303-1310.
3. Wheeler A.P., Bernard G.R. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 2007, 369(9572):1553-1564.
4. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420(6917):885-891.
5. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348(2):138-150.
6. Volk H.D., Reinke P., Docke W.D. Clinical aspects: from systemic inflammation to immunoparalysis. Chem Immunol 2000, 74:162-177.
7. Calder P.C. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 2003, 38(4):343-352.
8. Stubbs C.D., Smith A.D. The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophys Acta 1984, 779(1):89-137.
9. Murphy M.G. Dietary fatty acids and membrane protein function. J Nutr Biochem 1990, 1(2):68-79.
10. Calder P.C. The relationship between the fatty acid composition of immune cells and their function. Prostaglandins Leukot Essent Fatty Acids 2008, 79(3-5):101-108.
11. Bulger E.M., Maier R.V. Lipid mediators in the pathophysiology of critical illness. Crit Care Med 2000, 28(Suppl 4):N27-N36.
12. Palombo J.D., Lydon E.E., Chen P.L., et al. Fatty acid composition of lung, macrophage, and surfactant phospholipids after short-term enteral feeding with n-3 lipids. Lipids 1994, 29(9):643-649.
13. Tilley S.L., Coffman T.M., Koller B.H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001, 108(1):15-23.
14. Harris S.G., Padilla J., Koumas L., et al. Prostaglandins as modulators of immunity. Trends Immunol 2002, 23(3):144-150.
15. Petrak R.A., Balk R.A., Bone R.C. Prostaglandins, cyclo-oxygenase inhibitors, and thromboxane synthetase inhibitors in the pathogenesis of multiple systems organ failure. Crit Care Clin 1989, 5(2):303-314.
16. Prescott S.M., Zimmerman G.A., McIntyre T.M. Platelet-activating factor. J Biol Chem 1990, 265(29):17381-17384.
17. Marangoni F., Angeli M.T., Colli S., et al. Changes of n-3 and n-6 fatty acids in plasma and circulating cells of normal subjects, after prolonged administration of 20:5 (EPA) and 22:6 (DHA) ethyl esters and prolonged washout. Biochim Biophys Acta 1993, 1210(1):55-62.
18. Lee T.H., Menica-Huerta J.M., Shih C., et al. Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product. J Biol Chem 1984, 259(4):2383-2389.
19. Golman D.W., Goetzl E.J. Human neutrophil chemotactic and degranulating activites of leukotriene B5 (LTB5) derived from eicosapentaenoic acid. Biochem Biophys Res Commun 1983, 117:282-288.
20. Lee T.H., Hoover R.L., Williams J.D., et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 1985, 312(19):1217-1224.
21. Whelan J., Broughton K.S., Kinsella J.E. The comparative effects of dietary alpha-linolenic acid and fish oil on 4- and 5-series leukotriene formation in vivo. Lipids 1991, 26(2):119-126.
22. Kang J.X., Wang J., Wu L., et al. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature 2004, 427(6974):504.
23. Schaefer M.B., Ott J., Mohr A., et al. Immunomodulation by n-3- versus n-6-rich lipid emulsions in murine acute lung injury-role of platelet-activating factor receptor. Crit Care Med 2007, 35(2):544-554.
24. Mayer K., Kiessling A., Ott J., et al. Acute lung injury is reduced in fat-1 mice endogenously synthesizing n-3 fatty acids. Am J Respir Crit Care Med 2009, 179(6):474-483.
25. Ariel A., Serhan C.N. Resolvins and protectins in the termination program of acute inflammation. Trends Immunol 2007, 28(4):176-183.
26. Serhan C.N., Yang R., Martinod K., et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009, 206(1):15-23.
27. Serhan C.N. Systems approach to inflammation resolution: identification of novel anti-inflammatory and proresolving mediators. J Thromb Haemost 2009, 7(Suppl 1):44-48.
28. Serhan C.N., Clish C.B., Brannon J., et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000, 192(8):1197-1204.
29. Serhan C.N., Hong S., Gronert K., et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002, 196(8):1025-1037.
30. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and proresolution lipid mediators. Nat Rev Immunol 2008, 8(5):349-361.
31. Levy B.D., Kohli P., Gotlinger K., et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol 2007, 178(1):496-502.
32. Haworth O., Cernadas M., Yang R., et al. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 2008, 9(8):873-879.
33. Arita M., Yoshida M., Hong S., et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 2005, 102(21):7671-7676.
34. Arita M., Bianchini F., Aliberti J., et al. Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005, 201(5):713-722.
35. Arita M., Ohira T., Sun Y.P., et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 2007, 178(6):3912-3917.
36. Spite M., Norling L.V., Summers L., et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009, 461(7268):1287-1291.
37. Anand R.G., Alkadri M., Lavie C.J., et al. The role of fish oil in arrhythmia prevention. J Cardiopulm Rehabil Prev 2008, 28(2):92-98.
38. Calo L., Bianconi L., Colivicchi F., et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005, 45(10):1723-1728.
39. Heidt M.C., Vician M., Stracke S.K., et al. Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thorac Cardiovasc Surg 2009, 57(5):276-280.
40. O'Keefe J.H., Abuissa H., Sastre A., et al. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol 2006, 97(8):1127-1130.
41. Geelen A., Brouwer I.A., Schouten E.G., et al. Effects of n-3 fatty acids from fish on premature ventricular complexes and heart rate in humans. Am J Clin Nutr 2005, 81(2):416-420.
42. Pluess T.T., Hayoz D., Berger M.M., et al. Intravenous fish oil blunts the physiological response to endotoxin in healthy subjects. Intensive Care Med 2007, 33(5):789-797.
43. Michaeli B., Berger M.M., Revelly J.P., et al. Effects of fish oil on the neuro-endocrine responses to an endotoxin challenge in healthy volunteers. Clin Nutr 2007, 26(1):70-77.
44. Berger M.M., Tappy L., Revelly J.P., et al. Fish oil after abdominal aorta aneurysm surgery. Eur J Clin Nutr 2008, 62(9):1116-1122.
45. Mayer K., Seeger W. Fish oil in critical illness. Curr Opin Clin Nutr Metab Care 2008, 11(2):121-127.
46. Singer P., Shapiro H. Enteral omega-3 in acute respiratory distress syndrome. Curr Opin Clin Nutr Metab Care 2009, 12(2):123-128.
47. Pontes-Arruda A., Demichele S., Seth A., et al. The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data. JPEN J Parenter Enteral Nutr 2008, 32(6):596-605.
48. Mancuso P., Whelan J., DeMichele S.J., et al. Dietary fish oil and fish and borage oil suppress intrapulmonary proinflammatory eicosanoid biosynthesis and attenuate pulmonary neutrophil accumulation in endotoxic rats. Crit Care Med 1997, 25(7):1198-1206.
49. Gadek J.E., DeMichele S.J., Karlstad M.D., et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. Crit Care Med 1999, 27(8):1409-1420.
50. Singer P., Theilla M., Fisher H., et al. Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury. Crit Care Med 2006, 34(4):1033-1038.
51. Pontes-Arruda A., Aragao A.M., Albuquerque J.D. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med 2006, 34(9):2325-2333.
52. Marik P.E., Zaloga G.P. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med 2008, 34(11):1980-1990.
53. Heyland D.K. Nutrition clinical practice guidelines 4.1(b) composition of enteral nutrition: fish oils Available at:, Accessed January 31, 2009. http://www.criticalcarenutrition.com/docs/cpg/4.1bfish%20oils_FINAL.pdf.
54. McClave S.A., Martindale R.G., Vanek V.W., et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N). JPEN J Parenter Enteral Nutr 2009, 33(3):277-316.
55. Nelson J.L., DeMichele S.J., Pacht E.R., et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants on antioxidant status in patients with acute respiratory distress syndrome. JPEN J Parenter Enteral Nutr 2003, 27(2):98-104.
56. Pacht E.R., DeMichele S.J., Nelson J.L., et al. Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome. Crit Care Med 2003, 31(2):491-500.
57. Calder P.C. Immunonutrition in surgical and critically ill patients. Br J Nutr 2007, 98(Suppl 1):S133-S139.
58. Heyland D.K., Novak F., Drover J.W., et al. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 2001, 286(8):944-953.
59. Stapleton R.D., Martin T.R., Gundel S.J., et al. A phase II, randomized, double-blind, placebo-controlled trial of fish oil (eicosapentaenoic acid and docosahexanoic acid) on lung and systemic inflammation in patients with acute lung injury. Am J Respir Crit Care Med 2009, 179:A2169.
60. Rice T. Trial of omega-3 fatty acid, gamma-linolenic acid and antioxidant supplemention in the management of acute lung injury (Omega). Presented at American Thoracic Society International Conference. San Diego (CA). May 2009, 17.
61. Engel J.M., Menges T., Neuhauser C., et al. Anasthesiol Intensivmed Notfallmed Schmerzther 1997, 32(4):234-239. [in German].
62. Weimann A., Bastian L., Bischoff W.E., et al. Influence of arginine, omega-3 fatty acids and nucleotide-supplemented enteral support on systemic inflammatory response syndrome and multiple organ failure in patients after severe trauma. Nutrition 1998, 14(2):165-172.
63. Saffle J.R., Wiebke G., Jennings K., et al. Randomized trial of immune-enhancing enteral nutrition in burn patients. J Trauma 1997, 42(5):793-800. [discussion: 800-2].
64. Wibbenmeyer L.A., Mitchell M.A., Newel I.M., et al. Effect of a fish oil and arginine-fortified diet in thermally injured patients. J Burn Care Res 2006, 27(5):694-702.
65. Cerra F.B., Lehman S., Konstantinides N., et al. Effect of enteral nutrient on in vitro tests of immune function in ICU patients: a preliminary report. Nutrition 1990, 6(1):84-87. [discussion: 96-8].
66. Bower R.H., Cerra F.B., Bershadsky B., et al. Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit Care Med 1995, 23(3):436-449.
67. Galban C., Montejo J.C., Mesejo A., et al. An immune-enhancing enteral diet reduces mortality rate and episodes of bacteremia in septic intensive care unit patients. Crit Care Med 2000, 28(3):643-648.
68. Suchner U., Katz D.P., Furst P., et al. Impact of sepsis, lung injury, and the role of lipid infusion on circulating prostacyclin and thromboxane A(2). Intensive Care Med 2002, 28(2):122-129.
69. Calder P.C. Rationale for using new lipid emulsions in parenteral nutrition and a review of the trials performed in adults. Proc Nutr Soc 2009, 68:252-260.
70. McCowen K.C., Friel C., Sternberg J., et al. Hypocaloric total parenteral nutrition: effectiveness in prevention of hyperglycemia and infectious complications-a randomized clinical trial. Crit Care Med 2000, 28(11):3606-3611.
71. Battistella F.D., Widergren J.T., Anderson J.T., et al. A prospective, randomized trial of intravenous fat emulsion administration in trauma victims requiring total parenteral nutrition. J Trauma 1997, 43(1):52-58. [discussion: 58-60].
72. Heyland D.K., Dhaliwal R., Drover J.W., et al. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr 2003, 27(5):355-373.
73. Mayer K., Gokorsch S., Fegbeutel C., et al. Parenteral nutrition with fish oil modulates cytokine response in patients with sepsis. Am J Respir Crit Care Med 2003, 167(10):1321-1328.
74. Mayer K., Fegbeutel C., Hattar K., et al. Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Intensive Care Med 2003, 29(9):1472-1481.
75. Heller A.R., Rossler S., Litz R.J., et al. Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med 2006, 34(4):972-979.
76. Wang X., Li W., Li N., et al. Omega-3 fatty acids-supplemented parenteral nutrition decreases hyperinflammatory response and attenuates systemic disease sequelae in severe acute pancreatitis: a randomized and controlled study. JPEN J Parenter Enteral Nutr 2008, 32(3):236-241.
77. Friesecke S., Lotze C., Kohler J., et al. Fish oil supplementation in the parenteral nutrition of critically ill medical patients: a randomised controlled trial. Intensive Care Med 2008, 34(8):1411-1420.
78. Weiss G., Meyer F., Matthies B., et al. Immunomodulation by perioperative administration of n-3 fatty acids. Br J Nutr 2002, 87(Suppl 1):S89-S94.
79. Barbosa V.M., Miles E.A., Calhau C., et al. Effects of a fish oil containing lipid emulsion on plasma phospholipid fatty acids, inflammatory markers, and clinical outcomes in septic patients: a randomized, controlled clinical trial. Crit Care 2010, 14(1):R5.
80. Preiser J.C., Chiolero R., Wernerman J. Nutritional papers in ICU patients: what lies between the lines?. Intensive Care Med 2003, 29(2):156-166.